Abstract:7527 Background: Endostatin is one of the most effective inhibitors of tumor angiogenesis. Clinical studies have shown that chemotherapy combined with endostatin could improve response rate and the survival of patients. Methods: Chemotherapy-naive consenting patients with stage IIIB/IV NSCLC, performance status (PS) 0-2, aged 18-75 years and normal organ function, who had stable disease (SD) or above after receiving a first cycle TC, were enrolled in this study. Eligible patients were randomly assigned to the endostatin treatment group (TC + endostatin. T:175 mg/m2 d1, C:AUC = 5 d1, endostatin:7.5 mg/m2, d8-d21,q3w) or the control group (TC + placebo), and received three cycles of chemotherapy. The primary endpoint was time to progression (TTP); secondary endpoints were objective response rate (ORR), progression-free survival (PFS), clinical benefit rate (CBR), and safety. Results: From Jul 2007 to Aug 2008, 126 patients were randomized 1: 1 to the endostatin treatment group (Arm E) and the control group (Arm C).The ORR was 39.3% in Arm E and 23.0% in Arm C. The ORR of patients treated with endostatin plus chemotherapy increased 16.3% over those treated only with chemotherapy (p = 0.078). The CBR was 90.2% in Arm E and 67.2% in Arm C, and there was a significant difference between the two groups (p = 0.004). The median TTP in Arm E and Arm C were 7.1 and 6.3 months, respectively. The 24-week hazard ratio (HR) was 0.416 (95% confidence interval: 0.209-0.827, p = 0.012). The 16-week rates of PFS in Arm E and Arm C were 90% and 75%, respectively (p = 0.033). The 24- week rates of PFS in Arm E and Arm C were 78% and 59%, respectively (p = 0.017). Survival profile need further follow-up. There was no significant difference in the incidence rates of adverse events and serious adverse events between the two groups. Conclusions: In previously untreated advanced NSCLC, treatments with TC plus endostatin could significantly improve the 16-week and 24-week rates of PFS, ORR and CBR. The safety profile was similar. Chemotherapy combined with endostatin might play a role in the improvement of response rate and the survival of patients with advanced NSCLC. No significant financial relationships to disclose.

Effect of Cinobufacini tablets, Erbitux Injection Combined with Chemotherapy on Patients with Advanced Non-small Cell Lung Cancer

Efficient Killing Effect of Osteosarcoma Cells by Cinobufacini and Cisplatin in Combination.

Effect of Cinobufacini plus platinum-based chemotherapy regimen on the immune function of patients with non-small-cell lung cancer: A meta-analysis

Clinical effect of anlotinib in combination with docetaxel in treating advanced non-small cell lung cancer

Effect of Gefitinib Combined with Compound Matrine Injection on Patients with Advanced Lung Cancer after Chemotherapy

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Cinobufotalin effect and mechanism on serum MMP-2, MMP-9, Beclin1, LC3-II in advanced NSCLC patients

Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC

Rh-endostatin (YH-16) in Combination with Chemotherapy for Advanced Non-Small Cell Lung Cancer: A Clinical Observation

Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.

Clinical Study of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Treatment of Patients with Advanced Non-Small-cell Lung Cancer

Influences of China-Made Gemcitabine Plus Platinum Regimen on the Quality of Life among Patients with Advanced Non-Small Cell Lung Cancer

Xiaoaiping Injection Combined with Cisplatin and Gemcitabine for Non-Small Cell Lung Cancer: A Clinical ObservationΔ

Three Cisplatin-Based Regimens in Treatment of Advanced Non-Small Cell Lung Cancer

The Efficacy of Pemetrexed Combined Cis-platinum Chemotherapy for Patients with Advanced Non Small Cell Lung Cancer and the Effect on Serum Tumor Markers

Clinical observation of paclitaxel liposome combined with capecitabine in the treatment of advanced gastric cancer

Clinical Observation on Concurrent Radiotherapy in Combination with Vinorelbine and Cisplatin for Advanced Non-small-cell Lung Cancer

Intercalated combination of chemotherapy for advanced non-small cell lung cancer patients with secondary drug resistance to epidermal growth factor receptor-tyrosine kinasas inhibitors therapy

The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis